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Abstract: Many genomic assays that assess recurrence risk in early breast cancer (EBC) are prognostic,
but they differ in risk group stratification, which can affect clinical utility. Prospective outcomes of >60K
patients treated based on the 21-gene assay results have shown that chemotherapy may be safely omitted
in EBC patents with low Recurrence Score (RS) results (RS<18). Because of its extensive validation
and wide clinical use, the RS assay is a common comparator in head-to-head studies with other assays.
Published / presented studies of the RS assay performed on the same tumor samples with Breast Cancer
Index (BCI), EndoPredict (EP) or EP+clinical features (EPclin), MammaPrint (MMP), and/or Prosigna
(ROR) assays were reviewed. Study findings were summarized descriptively. 14 studies were found that
compared the RS assay with BCI (1), BCI, EPclin, and ROR (1), EP/EPclin (2), MMP (6), and ROR
(4). Overall discordance in risk stratification ranged from 42% to 66% between assays. The RS assay
classifies 12% of patients as high risk, compared with EP (63%), EPclin (48%), and MMP (46%) assays
with dichotomous low/high risk groups, and compared with BCI (16%) and ROR (33%), assays that,
like the RS assay, use three risk groups. The five most common genomic assays in clinical use for EBC
risk stratify patients differently and thus are not interchangeable. Of these, the RS assay classifies the
smallest proportion of patients as high risk and would therefore be expected to result in the fewest
patients receiving chemotherapy. This article is protected by copyright. All rights reserved.
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ABSTRACT 
Many genomic assays that assess recurrence risk in early breast cancer (EBC) are 
prognostic, but they differ in risk group stratification, which can affect clinical utility. 
Prospective outcomes of >60K patients treated based on the 21-gene assay results have 
shown that chemotherapy may be safely omitted in EBC patents with low Recurrence Score 
(RS) results (RS<18). Because of its extensive validation and wide clinical use, the RS assay 
is a common comparator in head-to-head studies with other assays. Published / presented 
studies of the RS assay performed on the same tumor samples with Breast Cancer Index 
(BCI), EndoPredict (EP) or EP+clinical features (EPclin), MammaPrint (MMP), and/or 
Prosigna (ROR) assays were reviewed. Study findings were summarized descriptively.  
14 studies were found that compared the RS assay with BCI (1), BCI, EPclin, and ROR (1), 
EP/EPclin (2), MMP (6), and ROR (4). Overall discordance in risk stratification ranged from 
42% to 66% between assays. The RS assay classifies 12% of patients as high risk, 
compared with EP (63%), EPclin (48%), and MMP (46%) assays with dichotomous low/high 
risk groups, and compared with BCI (16%) and ROR (33%), assays that, like the RS assay, 
use three risk groups. The five most common genomic assays in clinical use for EBC risk 
stratify patients differently and thus are not interchangeable. Of these, the RS assay 
classifies the smallest proportion of patients as high risk and would therefore be expected to 
result in the fewest patients receiving chemotherapy.  
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INTRODUCTION 
Many genomic assays available to assess recurrence risk in early breast cancer are 
prognostic, however, they differ in classifying patients into risk groups, resulting in potential 
differences in clinical utility and treatment decisions. These assays include the RS by the 21-
gene Oncotype DX® Breast test, the 70-gene signature of the MammaPrint test, the 11-gene 
based EP/EPclin score by EndoPredict, the ROR score based on 46 of the 50 genes in the 
PAM50 signature by Prosigna, and the Breast Cancer Index (BCI), which combines a ratio of 
the HOXB13/IL17BR (H:I) genes with a 5-gene genomic grade component. These assays 
have been validated in distinct populations, as shown in Table 1 and Table 2. Of note, the 
validation cohorts of these assays differ not only in menopausal and nodal status, but also in 
terms of breast cancer estrogen and HER2 receptor status, and endocrine therapies 
received 1-12. Differences in the validation cohort compositions are essential to consider when 
assays are compared with each other in terms of prognostic ability and prediction of 
treatment benefit.  
 
Many of the above-mentioned multigene assays have been validated in retrospective studies 
such as the ABCSG 6/8 cohort for EP/EPclin and the ATAC and ABCSG8 cohorts for the 
ROR scores5, 13, 14 15. While the initial validation data for MammaPrint relied on assessments 
of archived tumors from heterogeneous and largely untreated patient cohorts, the 
prospective MINDACT trial has yielded higher quality prognostic validation evidence from 
randomized patient cohorts 11, 16, 17. The identification of patients with high clinical risk and 
low genomic score with at least a 92.5% chance of being free of distant metastasis without 
chemotherapy at 5 years was demonstrated using the Mammaprint assay in the MINDACT 
trial17. Prospective outcomes in >60,000 patients (including both clinical and epidemiological 
data) treated based on 21-gene assay results have shown that patients within the low RS 
group (RS<18) have excellent outcomes without chemotherapy 18-24. The prognostic power of 
the RS was validated in an endocrine  treated NSABP B14 cohort, in the Kaiser Permanante, 
JBCRG, SWOG 8814 and in the transATAC sudies 8, 25.3, 26, 27 1. The predictive power of RS 
for the prediction of chemotherapy benefit was initially validated in the NSABP B20 study in 
endocrine only vs. chemoendocrine treated cohorts. 9. Additionally, the recently published 
prospective TAILORx study demonstrates the ability to safely avoid adjuvant chemotherapy 
This article is protected by copyright. All rights reserved.
in a larger proportion of patients with node negative disease, those with RS results from 0-25 
28. The power of chemotherapy benefit using the Mammaprint test was tested in the 
MINDACT trial 201617 . Prediction of prognosis in chemotherapy treated patients was 
validated for the RS in the NASBP B28, PCAS-01, for Prosigna in the DBCG77B trial. 29  and 
for Endopredict in the GEICAM/9906 trials 28 30 31. The prognostic power of Mammaprint in 
untreated patients was validated in the TRANSBIG study16 . Because of its extensive 
validation and wide clinical use, the RS assay is a common comparator in head-to-head 
studies with other assays4, 32-44. 
 
In this retrospective systematic literature review, we addressed the question of discordance 
in genomic risk group classifications between the five commercially available tests. We 
reviewed and summarized results from 14 available studies in the literature, which compared 
distinct genomic scores and corresponding risk group classifications with each other when 
two or more assays were performed on the same tumor sample, and we used the RS as a 
basis for the comparison. 
 
MATERIALS AND METHODS 
Fourteen published and presented studies comparing the RS assay performed on tumor 
samples from the same patient cohorts with Breast Cancer Index (BCI), EndoPredict (EP) or 
EP+clinical features (EPclin), MammaPrint (MMP), and/or Prosigna (ROR) assays were 
identified and reviewed. Only studies with available data on discordance between different 
risk group classifications of patients between assays were included. Study findings were 
summarized descriptively. Distribution of risk group categories were extracted, and 
discordance between assays was determined. Overall discordance was defined as any 
difference in risk group classification, minor discordance as the difference of one risk 
category (low to intermediate, intermediate to low, high to intermediate, or intermediate to 
high), and major discordance as the difference of more than one risk category (low to high or 
high to low) between the RS assay and other. Additionally, an overview on five commercially 
available genomic tests (Mammaprint, Oncotype DX, Breast Cancer Index, Prosigna, 
Endopredict) was conducted with the focus restricted to validation sets and resulting 
classification scores (Table 1). 
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RESULTS 
 
Characteristics in validation cohorts of existing multigene assays 
The validation cohorts for the five multigene tests show distinct differences in risk group 
classifications that potentially affect prognostic utility of the assays. Pre- and 
postmenopausal status was included for all assays, however cut-off for definition of 
menopausal status (50 years vs 60 years), nodal status, inclusion of ER and/or HER2 status 
as well as tumor size differs in the different assays 1-8, 10-12, 45. As to nodal status, except for 
the BCI assay, node negative and node positive patients were both included in all cohorts. It 
is of note that the definition of nodal positivity differs; pN2 patients were included in the 
EP/EPclin score validation, but not in the validation cohorts for the other assays. Hormone 
receptor status also shows distinct differences as patients of any ER status were included in 
two tests (Mammaprint and Prosigna) whilst two other tests (Oncotype and Endopredict) 
included only ER positive patients for the validation design 1-8, 10-12, 45. The RS was initially 
validated in pre- and post-menopausal, node-negative ER-positive patients treated with 5-
years of hormonal therapy; however, subsequent validation evidence and prospective 
outcomes data have been generated in both node-negative and node-positive ER-positive, 
HER2-negative early breast cancer patients treated with adjuvant hormonal therapy (Detailed 
description of the multigene tests are shown in Table 1 and Table 2). 
A short summary of development of multigene tests follows: 
 
Mammaprint 
This 70 gene multigene test was first validated in 2002 on a virtually untreated cohort of 
young patients (less than 55 years-old with pT1/pT2 tumors, nodal negative/positive status, 
most not receiving adjuvant systemic therapy regardless of nodal status) 46. In the 
consecutive validation study, most node positive and some of the node negative patients 
received adjuvant systemic therapy 46. Genes included in Mammaprint are associated with 
proliferation, invasion and angiogenesis47. The test is performed centrally, conducted in 
Amsterdam, Netherlands. Mammaprint provides low and high risk genomic scores without 
including clinical parameters. High clinical risk coupled with low genomic profile identifies a 
heterogeneous group of patients with a risk of distant metastases at 5 years that likely does 
not exceed 7.5%  2, 7, 46. The difference between clinical and genomic risk groups (as low 
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genomic /high clinical risk versus high genomic/low clinical risk) was found not to differ 
significantly and showed no relevant effect in predicting chemotherapy benefit 11, 16, 17. 
 
Oncotype DX 
This 21 gene test was initially validated on the NSAPB-B14 and NSAPB-B20 prospective 
clinical trials including nodal negative and hormone receptor (ER) positive early breast 
cancer (pT1-2) patients receiving endocrine (tamoxifen) therapy (NSABP-B14) and 
endocrine (tamoxifen) or chemoendocrine therapy (NSABP-B20) 3, 8, 9. This is a centralized 
test as well, currently performed at Genomic Health (Redwood City, CA, USA). Involved 
genes are related to ER, HER2, proliferation and invasion/metastases. Oncotype DX 
provides continuous RS results between 0-100, providing information on distant recurrence 
at 10 years in all ER positive HER2 negative patients independently of tumor size or of nodal 
status 1. Predictive power of the RS test was repeatedly confirmed in clinical trials1, 9, 48. High 
RS results (RS >25) are predictive for large chemotherapy benefit9. On the contrary, the 
prospective TAILORx study recently reported 9-year outcomes showing no benefit from 
chemotherapy for node negative, ER positive HER2 negative patients with RS 11-25, and 
confirming excellent outcomes for those with RS 0-25 treated with hormone therapy alone. 1, 
9, 48 
 
Breast Cancer Index (BCI) 
This test of 5+2 genes was initially validated in 2008 and represents the combination of the 
molecular grade index (MGI) and the HOXB13:IL17BR ratio (H:I) 49. 
Genes in BCI are prognostic, associated with clinical outcome and the assay is performed 
centrally at Biotheranostic, San Diego, USA49. BCI reports low and high risk scores (between 
1-10) without the inclusion of clinical parameters. Patients of all age, with ER+/ HER2 
negative and nodal negative breast cancer undergoing adjuvant hormonal therapy are 
eligible for testing. High risk BCI can prognosticate distant recurrence at 5 years respectively 
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This 50 (50+8 reference genes) gene test was initially validated in 2009 in a postmenopausal 
patient subset independently of nodal status including all intrinsic subtypes 53. Genes in the 
Prosigna test are related to various molecular pathways and to tumor proliferation 54. The test 
is decentralized and can be performed by local pathology laboratories. The Prosigna test 
provides not only continuous ROR risk scores (scale 0-100) but also the intrinsic subtype 
(Luminal A or B, HER2, Basal-like). The ROR score is calculated using coefficients from a 
Cox model that includes the Spearman correlation of a 46-gene subset of the 50 genes to 
each intrinsic subtype centroid, a proliferation score, and gross tumor size (< 2 cm or > 2 
cm). Risk categories (low, intermediate, high) are derived from the ROR score and the nodal 
category (0 or 1–3 positive nodes). Additionally, the test has been approved by the FDA for 
use in postmenopausal patients. The prognostic value of ROR scores has been 
demonstrated in the transATAC and ABCSG08 studies, showing that the low ROR or 
Luminal A intrinsic subtype is associated with a very low 10 years distant recurrence4, 6, 14, 53. 
More recently, the Prosigna ROR score and intrinsic subtypes were shown to be prognostic 
in high-risk premenopausal patients with early breast cancer, and intrinsic subtype was 
predictive for adjuvant C/CMF treatment in this study 55 . No prospective data on Prosigna 
are available for predictive power for treatment benefit however. 
 
Endopredict 
This 11 +1 gene test was validated in 2011 in a ABCSG06 and ABCSG08 cohorts of ER 
positive postmenopausal patients independent of nodal status including pN0/pN1-pN2 
patients as well 5. Genes in the Endopredict test are ER and proliferation related genes. The 
test is de-centralized and can be performed in local pathology laboratories. The Endopredict 
test provides the EP score (0-15) and the EPclin score: the latter is a combination of EP 
Score + pT + pN. 5. The prognostic value of the Endopredict test is currently available as the 
EPclin score, whilst EP score is not reported separately in the commercially available tests. 
EPclin score can prognosticate 10 years distant recurrence, which is 4% at low EPclin and 
and 28% at high EPclin (group average in a particular study population). 5, 13, 31. No data on 
predictive power for treatment benefit are available for Endopredict. 
 
 
Characteristics of the 14 studies enrolled in the review 
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Fourteen studies ranging in size from 34 to 1007 patients were included in the current 
review, summarizing 5514 patients. Data on discordant results were available in 10 of 14 
studies. RS results were compared with BCI in one study, with MMP in four studies, with 
ROR in four studies, and with EP/EPclin in one study 4, 32, 33, 35, 37-39, 41, 42, 44. One further study, 
the 2016 TransATAC study, compared RS with BCI, ROR, and EPclin 39. As to nodal status, 
three of 14 studies included node-negative patients only (RS vs BCI in TransATAC 2016, RS 
vs ROR by Alvarado et al 2015, as well RS vs MMP by Maroun et al. 2015), whilst 11 of 14 
studies included node-positive patients as well 32, 38, 39. 
A list of the studies is shown in Table 3. 
 
Discordance between the assays 
Overall discordance in risk categorization between the RS assay and other genomic assays 
ranged from 42% to 66%. The most frequent comparisons were conducted between the RS 
assay and MMP (n=4) and the RS assay and ROR (n=3). In comparisons of the RS assay vs 
MMP, minor discordances ranged from 26% to 38% of cases, while major discordances 
ranged from 19% to 25% of cases. In comparing the RS assay vs ROR, minor discordances 
ranged from 37% to 45% of cases, while major discordances ranged from 3% to 20% of 
cases. In the only available study comparing the RS assay vs. EP/EPclin, minor discordance 
was detected in 29% of cases, while major discordance ranged from 18% to 21% of cases, 
and overall discordance was seen in 47%-50%. Comparing the RS assay vs BCI, minor 
discrepancies occurred in 37% and major discordance in 5% of the cases. A summary of the 
discrepant classification using different multigene assays is shown in Table 3. 
 
Risk group distribution by studies 
Among all studies, high-risk genomic score was classified in a range from 11.5% to 63% of 
patients. Of these genomic assays, the RS assay classifies the smallest proportion of 
patients as high risk (11.5%), whilst EPclin classifies the highest percentage of patients as 
high risk (63% for EP and 48.4% for EPclin). Even when compared with ROR and BCI, both 
of which, like the RS assay, classify patients into three risk categories, the RS test results in 
the lowest percentage of high-risk patients. For BCI, the intermediate group is as defined by 
Sestak et al15. A summary of individual risk classification is shown in Figure 1 and Figure 2. 
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Discussion 
In this review, we compared results of studies that reported comparisons of risk 
classifications of the 21-gene assay with one of four additional commercially available 
genomic tests used for treatment decision-making in early breast cancer. This review 
demonstrates that RS results classify the lowest proportion of patients as high-risk at 11.5% 
whilst EPclin classifies the highest proportion of patients as high-risk on the same tumor 
tissue at 63%. However, it is not clear if these discrepancies may result in over-treatment or 
under-treatment of patients. 
 
Differences in risk group classifications may arise from clinical and biologic differences in 
original study populations from which each assay was developed and validated as well as 
from different approaches to defining pre-specified cut-points across scores, and differences 
in the genes measured.  
The validation cohort for the EPclin assays was composed solely of postmenopausal ER+ / 
HER2- study patients5, 6, 53. The validation cohort for the Prosigna assay also included 
postmenopausal patients independently from intrinsic subtypes5, 6, 53,14 6.  As such, any “high 
risk” groups delineated by these tests may not be at the same level of risk when broader ER+ 
populations that include premenopausal patients or more obvious chemotherapy candidates 
are considered. Furthermore, different approaches to pre-specifying cut-points across scores 
also influence risk group classifications: assays defining dichotomous “high” or “low” risk 
groups, while seemingly convenient, may lose some accuracy in classifying patients whose 
recurrence risks are near those of the cut-point.  
 
Though all assays are based on gene expression algorithms producing composite scores 
that correlate with risks of recurrence, the assays may perform differently based on 
differences in genes and biologic pathways being measured as well as analytic factors that 
affect precision and accuracy. The latter factors include performance characteristics of 
genomic assessment platforms, quality control methods, and even differences in pre-analytic 
factors inherent in the processing of tissues for each assay 3, 33, 44. 54. 
 
The OPTIMA study conducted four prognostic tests on the same tumor blocks, including 
three genomic tests: RS by Oncotype DX, ROR by Prosigna and MammaPrint as well as 
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IHC4 33. In this comparative study, each test classified patients differently, with relatively low 
overall agreements between any two tests based on Kappa values varying between 0.33-
0.60 33. The highest percentage of low-risk genomic score was achieved by RS (81%), 
followed by IHC4 (72%), ROR (65%), and MammaPrint (61.4%) 33. In the transATAC study, a 
similar overall discordance rate of 42% was described in a node-negative hormone receptor-
positive patient population when BCI was compared with RS, resulting in reclassification 
(p=0.003), especially in the low-intermediate prognostic groups 39. A direct comparison of RS 
with EPclin scores by Buus et al. suggested superiority of EPclin in terms of prognostic 
information over RS; however node-positive (pN2) patients were included in this study as 
well 44. Since the EPclin result relies on an algorithm that heavily weights nodal status, it may 
be expected that the prognostic differences for high- and low-risk groups might be greater 
when nodal status is incorporated 44. Another study by Dowsett et al reported superiority of 
ROR in prognostic information to RS; however, more patients were classified as high risk by 
ROR than by RS 4. The inclusion of pN2 samples in validation cohorts might drive up the 
high-risk numbers. 
 
Patients identified as “high-risk” by any multigene assay are most likely to receive 
chemotherapy, with clear implications for toxicity, quality of life, treatment costs, and the 
likelihood of being over-treated. While each assay identifies patients at higher risks for 
recurrence, only the RS test has shown that their high-risk group represents patients for 
whom DFS and distant recurrence outcomes with chemotherapy treatment are superior to 
those achieved with hormone therapy alone. 1, 9  
 
An emerging number of papers have addressed the impact of multigene tests on adjuvant 
chemotherapy decisions by physicians. A recently published paper comparing MammaPrint 
and EndoPredict risk stratification showed a poor correlation between the two tests and 
noted that following EndoPredict results in the study, a change in therapy decisions in favor 
of adding chemotherapy to hormone therapy would have occurred in 38% of the patients 56. 
Another recent study by the SAKK 26/10 analyzed the decision impact of Oncotype DX 
testing and reported a change in therapy decision against chemotherapy and in favor of 
hormone therapy alone in 44% of the patients 57. A similar recent UK study reported a 
change against chemotherapy in favor of endocrine therapy alone in 69.2% of patients after 
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the Oncotype DX results were discussed in an interdisciplinary meeting 58. Interestingly, the 
West German Breast Cancer Study Group found that using the Prosigna assay resulted in 
29.3% discrepant intrinsic subtyping compared to routine IHC, with a change in therapy 
decisions in 18.2% of the patients, two-thirds (22 of 36 patients) switched from no 
chemotherapy to chemotherapy 59. 
 
Conclusion 
The five most common genomic assays in clinical use for early breast cancer each risk-
stratify patients differently, thereby carrying implications for the potential use of adjuvant 
chemotherapy. The proportion of patients classified as high risk differs in these tests, 
however it remains unclear whether this may lead to under- or overtreatment. Even when the 
risk group distribution appears similar between assays, there is considerable discordance in 
patient classification into these groups. As such, these assays should not be used 
interchangeably. Ultimately, the clinical utility of the individual genomic scores is best 
assessed in adequately powered prospective clinical trials that address a specific practical 
management issue.  
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Legend of Figures 
Figure 1. Pooled risk group distribution. 
RS groups defined as low (RS<18), intermediate (RS 18-30), and high (RS ≥ 31) 
 
Figure 2. Risk group distribution, by each study in the current comparison. 
[a] For BCI, the intermediate group is as defined in Sestak 2016 39. [b] The Tsai 2018 study 
sought to reclassify by MMP patients who were first classified as intermediate by the RS 
assay 43. RS groups defined as low (RS<18), intermediate (RS 18-30), and high (RS ≥ 31). 
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Abbreviations : ET (endocrine therapy), ER (estrogene), FFPE (formalin fixed paraffin embedded), LN (nodal status) 
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Table 2. Summary of major clinical validation studies on multigene tests 
 Trial author / published in Overall risk HR 
Prognostication in endocrine treated patients     
Oncotype DX n=668, ER+, pN0 NSABP B14 Paik / NEJM 2004 
(Ref.8) 
DRFS 10y- 85%  
 
2.81 
RS low 6.8% 
RS int 14.3% 
RS high 30.5% 
Oncotype DX 220 cases, 570 controls, 
ER+, pN0 
Kaiser Permanente Habel / Breast Cancer 
Research 2006 
(Ref.25) 
OS 10y- 92.7% 
 
Relative risk  
RR=2.4  
RS low 2.8% 
RS int 10.7% 
RS high 15.5% 
Oncotype DX ER+ 
pN0 = 200 ,pN+=80  
JBCRG  Toi / Cancer 2010 
(Ref.27) 
DRFS 10y- 91.5% 
 
6.03  
RS low 3.3% 
RS int 0 % 
RS high 24.8% 
Oncotype DX ER+ 
pN0=872, pN+=306 
transATAC  Dowsett / JCO 2010 
(Ref.3) 
pN0 DRFS 9y- 91.% 
pN+ DRFS 9y 76% 
pN0: 5.25 
pN+: 3.47 
Oncotype DX ER+ 
n=148 (HR therapy arm) 
SWOG 8814 Albain / Lancet Oncol 2010 
(Ref.1) 
pN+ OS: 68-2% 4.42 
Prosigna ER+ 
pN0=739, pN+=268 
transATAC Sestak / JCO 2015 
(Ref.15) 
pN0 DRFS 10y- 89.3.% 
pN+ DRFS 10y 69.8% 
pN0: 4.78 
pN+ (1-3): 1.98 
Prosigna ER+ 
pN0= 1047, pN+  
ABCSG08 Gnant / Ann Oncol 2014 
(Ref.6) 
pN0 DRFS 10y- 92.% 
pN+ DRFS 10y 84% 
2.85 
Prosigna ER+ / HER2- pN0=1,163, 
pN+=1395 
DBCG 77B Lænkholm / JCO 2018  
(Ref.29) 
pN0 ROR low / int. / high: 
  95% / 92.7% / 82.2% 
pN+ ROR low / int. / high: 
  96.5% / 88.5% / 79.1% 
pN0/+ Luminal A / B: 
0.56 (low vs. 
intermediate) 
1.79 (high vs. 
intermediate) 
1.92 (Luminal B vs. 
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n= 378, pN0 (60%) 
ABCSG06 Filipits / Cin Cancer Res 
2011 
(Ref.5) 
DRFS 10 y -88% 
 
1.19  
EPclin low risk 4% 
EPclin high risk 28% 
Endopredict ER+ 
n=1324, pN0 (70.6%) 
pN+: 29%  
(pN1 26.4%, pN2 2.8%) 
 
ABCSG08 Fitzal / Br J Cancer 2015 
(Ref.13) 
DRFS 10 y- 93% 
 
1.16-1.48 (1.26) 
EP High risk 91% 
EP Low risk 97.5% 
Prediction of chemotherapy benefit     
Oncotype DX n=651 
randomized-retrospective 
NSABP-20 Paik / JCO 2006 
(Ref.9) 
10y DRFS:  
92.2% Chemo+ TAM 




High RS: 0.26 
Oncotype DX n=367 
randomized-retrospective 
SWOG 8814 Albain / Lancet Oncol 2010 
(Ref.1) 
10y DRFS:  
64.8% chemo + TAM 




High RS: 0.52 
Oncotype DX n=19719 
ER+/HER2- 
pN0 
RS 11-25  
randomized-prospective 
 
TailorX Sparano / NEJM 2018 
(Ref.48) 
9y DFS 









premenopausal, high risk 
(either N+, >5cm or 
DBCG 77B Jensen / BCR 2018 
(Ref.55) 
10y OS 
59.7% with C 
62.2% with CMF 
Chemotherapy 
benefit (C/CMF): 
 Luminal B: 0.61 
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infiltrating fascia) 
randomized-retrospective 
41.1% with levamisole 
46.0% control arm 
 Basal-like: 0.44 
Mammaprint ER+/- (88.4% vs.11.6%) 
HER2 +/- (93% vs. 9.5%) 
n=6693  
pN0 (79%) 
pN+: 21%  
(pN1 20.9%, pN2 0.1%) 
randomized-prospective 
 
Mindact Cardoso / NEJM 2016 
(Ref.17) 
Chemotherapy benefit:  
Low genomic/ 
High clinical: 1.5% 
 
High clinical / 
low genomic  
0.63 (DFS),  
0.64 (OS) 
Low clinical / 
High genomic  
0.74 (DFS) 
0.72 (OS) 
Prognostic in chemotherapy treated patients     
Oncotype DX n=1019 NSABP B28 Mamounas / J Nat Can Inst 
2017  
(Ref.28) 
10y DFS: 59% RS: 2.59  
Nodal status: 1.91 
 




73.2% with FEC 
78.4% with FEC-D 
RS: 2.66 
Nodal status: 2.65 
 
Endopredict n=556 GEICAM/9906 Martin / BREA 2014 
(Ref.31) 
10 y MFS; 78.5% EP: 1.126 
Nodal status: 1.4-3.6 
Untreated patients     
Mammaprint n=307 TRANSBIG Buyse / J nat Cancer Inst 
2006 
(Ref.16) 




Overall Risk reflects the outcomes for patients receiving ET (endocrine therapy) alone, who had "favorable" or "low" genomic scores. 
Abbreviations:  ER: estrogene receptors, DRFS: Disease and recurrence free survival, DFS: Disease free survival, OS: overall survival. MFS: metastasis free 
survival.HR: hazard ratio (unit changes). 
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Table 3. Discordance between genomic assays 
  Discordance
a
 Between the RS Assay and Other Assays 
 n= BCI ROR EP / EPclin MMP 
  Minor 
(L ↔ I or 
I ↔ H) 
Major 
(L ↔ H) 
Overall Minor 
(L ↔ I or I 
↔ H) 
Major 
(L ↔ H) 
Overall Minor 






(L ↔ I 







(Sestak 2016)  
(Ref. 39) 
665 37% 5% 42%          
OPTIMA 
(Bartlett 2016)  
(Ref. 33) 
302    40% 10% 50%       
Marin General Hospital 
(Alvarado 2015) 
(Ref. 32)  
52    37% 10% 46%       
TransATAC  
(Dowsett 2013) 
(Ref. 4)  
1007    41% 3% 43%       
Heidelberg cohort  
(Sinn 2017)  
(Ref. 42) 
47    45% 20% 66%       
Swiss Study  
(Varga 2013)  
(Ref. 44) 




   
French Study  
(Svedman 2013)  
(Ref. 35) 
67          38% 19% 57% 
US Oncology/UCSF Study  
(Denduluri 2011)  
(Ref. 37) 
53          34% 25% 58% 
McGill US Study  
(Maroun 2015)  
(Ref. 38) 
86          31% 22% 53% 
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Florida Study  
(Shivers 2013)  
(Ref. 41) 
148          26% 19% 44% 
[a] Overall discordance=any difference in risk classification between the RS assay and other; minor discordance=difference of one risk category 
(low ↔ intermediate or intermediate ↔ high); major discordance=difference of more than one risk category (low ↔ high). 
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